Definium begins second phase 3 study of DT120 for depression

May 12, 2026 7:00 AM

Definium Therapeutics (NASDAQ: DFTX) has dosed the first patient in Ascend, its second phase 3 study evaluating DT120 ODT for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found